Semax vs Cerebrolysin
Both Semax and Cerebrolysin are used for cognitive and neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Cerebrolysin
Evidence BCerebrolysin (porcine brain peptide complex)
A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
View full Cerebrolysin profile →Side-by-Side
| Attribute | Semax | Cerebrolysin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders | Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia |
| Typical Dose | 200–600 mcg intranasal, morning | Trial range: 5–30 mL daily (intravenous infusion) |
| Clinics Indexed | 89 | 41 |
| Categories | cognitive, neuroprotection | cognitive, neuroprotection |
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Key reported benefits — Cerebrolysin
- ✓Stroke recovery support
- ✓TBI rehabilitation
- ✓Cognitive function in dementia
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.